Syndicated News

This blog is still in BETA

We are aware of any formatting errors. These stories are automatically pulled from RSS feeds. Due to the automated nature of the post, some images may appear small, and some links may not be clickable until our staff has had the opportunity to manicure the postings. Thank you for understanding.

October 23, 2014

Sangamo IND for hemophilia B slated for Q2 2015 - Seeking Alpha (registration)

October 23, 2014/ Guest User

http://bit.ly/1FLtC95

Sangamo IND for hemophilia B slated for Q2 2015Seeking Alpha (registration)Sangamo Biosciences (NASDAQ:SGMO) says its plans to submit an IND to the FDA for the treatment of hemophilia B based on its zinc finger nuclease (ZFN)-mediated In Vivo Protein Replacement Platform (IVPRP). It will be the first therapeutic application ...Sangamo BioSciences Announces Target Date For First IND For Sangamo's In ...

from Hemophilia - Google News http://bit.ly/1FLtBlN via IFTTT

Committee of Ten Thousand

ADVOCATES FOR PERSONS WITH HIV/AIDS, HEMOPHILIA, HCV, AND SICKLE CELL

MONITORING THE BLOOD SUPPLY AND PROTECTING PATIENT RIGHTS SINCE 1989

The Committee of Ten Thousand is a grass-roots, peer-led, education, advocacy and support organization. The majority of our constituency is persons with hemophilia who contracted HIV/AIDS from tainted blood products. We work in solidarity with all communities affected by the HIV/AIDS pandemic. COTT advocates for disenfranchised chronic disease communities, especially those communities dependent on a safe national blood supply. We are dedicated to the belief that persons with HIV/AIDS and all chronic diseases can lead productive and healthy lives.

Find us on Facebook

Our Facebook Page

Stay in the debate! Join our discussion group!

Stay up to date! Join the mailing list!